What are the current management updates for epidermolysis bullosa simplex caused by recessive PLEC mutations with associated muscle weakness?

Epidermolysis Bullosa Simplex with Muscle Weakness: Current Updates

Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD) caused by recessive PLEC mutations requires vigilant long-term monitoring for progressive muscle weakness, cardiac involvement, and multisystem complications, as the phenotype is highly variable and muscle weakness may develop years after initial skin manifestations.

Classification and Molecular Basis

EBS with muscle weakness is caused by autosomal recessive mutations in the plectin gene (PLEC), which encodes a cytoskeletal crosslinker protein 1. The disease is classified as "basal EBS" where blistering occurs within the basal epidermis, with plectin showing absent or reduced expression on immunofluorescence 1.

Key Genotype-Phenotype Correlations

The location of PLEC mutations determines clinical manifestations 2, 3:

• EBS-MD: Most commonly linked to mutations affecting exon 31 (the central rod domain), though mutations can occur in all exons 2
• EBS with pyloric atresia (EBS-PA): Typically involves mutations in distal exons 1-30 and 32 2
• Combined phenotypes: Mutations in exon 32 can cause both pyloric atresia AND muscular dystrophy 3

Clinical Manifestations and Updates

Expanded Phenotypic Spectrum

Recent reports have significantly broadened the recognized clinical presentations 4, 2, 5:

Cutaneous features:

• Skin blistering from birth or early childhood
• Nail dystrophy (frequently reported) 4
• Improvement of skin manifestations with age is possible 2

Muscular involvement:

• Progressive limb-girdle muscular dystrophy (classic presentation)
• Upper limb-predominant weakness (newly recognized) 5
• Delayed onset of muscular dystrophy—can appear years after initial skin symptoms 2
• Precocity of muscle weakness correlates with mutation type and location 2

Newly recognized multisystem involvement 4, 2, 5:

• Laryngeal involvement with hoarseness of voice 4
• Bladder involvement 2
• Esophageal involvement 2
• Myasthenic syndrome features without limb-girdle involvement 4
• Subtle cardiomyopathy 5
• Respiratory and gastrointestinal manifestations of varying severity 4

Critical Pitfall

Muscular dystrophy has historically never been identified in EBS-PA patients, even in severe forms—until the first documented case in 2010 3. This means clinicians must monitor ALL patients with PLEC mutations for potential muscle weakness development, regardless of initial phenotype.

Pathological Features

Skeletal muscle biopsies reveal 6:

• Severe dystrophic changes with fiber size variation
• Degenerative myofibrillar alterations
• Mitochondrial abnormalities
• Pathological desmin-positive protein aggregates
• Disorganized myofibrils and sarcomeres
• Z- and I-band alterations
• Autophagic vacuoles and cytoplasmic bodies
• Misplaced and degenerating mitochondria

Diagnostic Approach

Essential diagnostic steps:

1. Immunofluorescence antigen mapping of skin biopsy showing absent or reduced plectin staining 1, 4

2. Molecular genetic testing:

   • Initial targeted PLEC gene panel
   • If only one variant identified, proceed to trio exome sequencing 5
   • RNA/transcript analysis is crucial for identifying cryptic intronic variants causing intron retention and frameshift mutations 5

3. Baseline muscle evaluation even in absence of weakness:

   • Clinical muscle strength assessment
   • Consider baseline CK levels
   • Cardiac evaluation for subtle cardiomyopathy 5

Management Algorithm

Immediate Management

Skin care:

• Minimize trauma to prevent blister formation
• Gentle wound care protocols
• Dapsone may provide dramatic response in select cases without extracutaneous involvement 7

Oral/dental care:

• Early dental referral mandatory 8
• Atraumatic techniques for all procedures
• Preventive-focused approach
• Behavior modification to minimize soft tissue injury 8

Long-term Monitoring Protocol

All patients with PLEC mutations require lifelong surveillance 2:

1. Muscular assessment (every 6-12 months):

   • Serial muscle strength examinations
   • Monitor for limb-girdle weakness or upper limb predominance
   • Assess for myasthenic features (fatigability, fluctuating weakness)
   • CK levels if weakness develops

2. Cardiac monitoring:

   • Baseline echocardiogram
   • Periodic cardiac evaluation for cardiomyopathy 5

3. Multisystem surveillance:

   • Voice/laryngeal assessment if hoarseness develops 4
   • Gastrointestinal symptoms (dysphagia, reflux) 2
   • Urinary symptoms 2
   • Respiratory function 4

4. Prenatal diagnosis available for subsequent pregnancies 9

Special Considerations for Adult-Onset Cases

Adult-onset presentations are now recognized 5, requiring:

• High index of suspicion in patients with childhood EBS who develop new weakness
• Combined myopathic and myasthenic features may coexist
• Consider CMS gene panel testing if myasthenic features present

Prognosis Updates

Long-term survival is possible in EBS-PA with skin improvement over time, but delayed-onset muscular dystrophy remains probable 2. The severity and timing of muscle weakness correlate with specific mutation types and locations, though no correlation with mucosal involvement has been established 2.